MiniMed 670G hybrid closed-loop system,
does it really help with Increased time in range in adults with type 1 diabetes?
research showsThe grade is C with 50 points. At 26 weeks, TIR 70-180 mg/dL was 70% versus 55%, adjusted absolute difference 15 points (95% CI 11-19), about 3.6 hours per day.
ads claimVerdict 895 is A with 84 points, verdict 995 is B with 78 points, and verdict 1014 is B with 77 points; they ask medication and insulin-delivery questions in type 1 diabetes. This verdict asks a device-and-algorithm question. Closed-loop access and reimbursement are real Korean decisions, but current models and coverage require separate checking.
Useful facts when choosing a product
- Control did not use real-time CGM.
- Medtronic supplied devices and technical support.
- A 15-point TIR increase is about 3.6 hours daily.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.minimed-hybrid-closed-loop-system.UNK.time-in-range-with-type-1-diabetes.increase.UNKUnknown > MiniMed hybrid closed-loop system > Unknown > time in range with type 1 diabetes > Increase claim > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Seven Australian university hospitals randomized 61 to HCL and 59 to control. Control was MDI or pump with fingerstick monitoring, not manual insulin plus real-time CGM; masked CGM measured outcomes only. Limitation name: small trial. Avoidability: possible - at least 200 participants could have been recruited to better assess rare safety events and attrition. Limitation name: open device use. Avoidability: impossible - users cannot be blinded to a worn pump and auto mode. Objective masked CGM prevented this from becoming an additional counted bias. Public grants predominated, but Medtronic supplied HCL systems, masked CGM devices, and technical support, with related author disclosures, so independence is I1.
Why this is classified as C (50)
Randomization and a large effect help, but a surrogate primary outcome, small sample, and in-kind manufacturer support give C.
Counterpoint. Benefit versus modern sensor-augmented therapy may be smaller than versus fingerstick-based control.
Rejudgment record. Cross-check applied — Cross-checked Diabetes Care report, protocol, and registry for TIR, comparator, duration, safety, and Medtronic in-kind support
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Increased TIR | C | The increase was 15 points but remains surrogate. |
| Serious safety | ? | Zero severe hypoglycemia or DKA cannot exclude rare harm. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| McAuley SA et al. 2020 Australian HCL RCT | Seven-center open-label 26-week RCT with masked-CGM outcome measurement | 120; HCL 61, control 59 | JDRF, ARC, and NHMRC grants; Medtronic in-kind HCL, CGM, and technical support | Masked-CGM TIR 70-180 mg/dL during the final three weeks | 70% versus 55%; absolute difference 15 points (95% CI 11-19) | Small single device trial with surrogate outcome |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Final verification and publication gate: Codex · Evidence date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] MiniMed 670G Hybrid Closed-Loop for Time in Range in Adults With Type 1 Diabetes - Benefit — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/minimed-670g-hybrid-closed-loop-time-in-range-adults-type-1-diabetes/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.